New hope for rare brain tumor: drug trial targets regrowth
NCT ID NCT06970145
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests the safety and effectiveness of anlotinib, a drug that blocks blood vessel growth, in 57 adults whose craniopharyngioma has come back after surgery. The main goal is to see if the drug shrinks the tumor. Researchers will also track how long the tumor stays controlled and any side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRANIOPHARYNGIOMAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Southern Medical University, Nanfang Hospital, Department of Neurosurgery
RECRUITINGGuangzhou, Guangdong, 510515, China
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.